Life sciences company specializing in developing psychedelic and naturally-sourced therapies to treat brain injuries Wesana Health Holding Inc. (CSE: WESA) (OTCQB: WSNAF) announced having closed the acquisition of provider of education, clinical care and clinical tools for psychedelic medical sector PsyTech Inc.
“The team at PsyTech has developed a leading platform for the treatment of neurological health that significantly accelerates Wesana’s technical capabilities and go-to-market strategy. With the closing of this acquisition and having the additional bench strength of the PsyTech team, we are one large step closer to accomplishing our goal of improving neurological health and performance of patients across the United States,” said Wesana’s CEO, Daniel Carcillo.
PsyTech will now exist as a fully owned subsidiary of Wesana Health. Wesana says this acquisition brings its total number of subsidiaries to three and this is a major step in helping the company to expand its business.
The company further announced it has commenced the process of applying to get its subordinate voting shares listed on the United States main stream stock exchange markets.